What is Scala Biodesign?
Scala Biodesign is a biotechnology firm specializing in the development of advanced computational platforms for the design and optimization of proteins. These proteins are crucial components for pharmaceuticals, chemicals, and sustainable industries. By integrating artificial intelligence, evolutionary data, and structural modeling, Scala Biodesign enhances the stability, activity, and manufacturability of biologics such as enzymes and antibodies. The company is recognized as a key player in the burgeoning field of AI-driven protein engineering, offering a pathway to accelerate bioproduct development and reduce the complexities associated with traditional experimental methods.
How much funding has Scala Biodesign raised?
Scala Biodesign has raised a total of $21.5M across 2 funding rounds:
Angel/Seed
$5.5M
Series A
$16M
Angel/Seed (2023): $5.5M with participation from TLV Partners
Series A (2026): $16M led by Grove Ventures Ltd, TLV Partners, Deep Insight, and Israel Innovation Authority
Key Investors in Scala Biodesign
Grove Ventures Ltd
Grove Ventures is a venture capital firm focused on early-stage investments, particularly in Israeli entrepreneurs. They manage significant capital and partner with founders building future-oriented technologies.
TLV Partners
TLV Partners is an early-stage venture capital firm based in Israel, investing in innovative startups across sectors like AI and healthcare. They aim to support exceptional teams in creating category-defining companies.
Deep Insight
Deep Insight Innovations is an Israeli fund dedicated to deep tech opportunities across various sectors including semiconductors and bio-convergence. They invest in pioneering solutions and advanced technologies.
What's next for Scala Biodesign?
With the recent infusion of major strategic investment, Scala Biodesign is poised for accelerated growth and market expansion. The company's focus on AI-driven protein engineering positions it to capitalize on the increasing demand for novel biologics across various industries. Future developments are expected to center on further refining its computational platforms, expanding its application into new therapeutic areas, and forging strategic partnerships to bring its optimized proteins to market. This substantial backing will likely fuel research and development initiatives, enhance its commercialization efforts, and solidify its competitive advantage in the rapidly evolving biotechnology landscape.
See full Scala Biodesign company page
